Semaglutide ya Diyabete yo mu bwoko bwa 2

Semaglutide ni igisekuru gishya cya GLP-1 (glucagon-isa na peptide-1) igereranya, kandi semaglutide ni dosiye ikora igihe kirekire yakozwe ishingiye ku miterere shingiro ya liraglutide, igira ingaruka nziza mu kuvura diyabete yo mu bwoko bwa 2. Novo Nordisk yarangije ubushakashatsi 6 Icyiciro cya IIIa cyo gutera inshinge za semaglutide, anatanga icyifuzo gishya cyo kwandikisha imiti yo gutera inshinge za semaglutide buri cyumweru mu kigo cy’Amerika gishinzwe ibiryo n’ibiyobyabwenge (FDA) ku ya 5 Ukuboza 2016. Icyifuzo cyo kwemerera ibicuruzwa (MAA) nacyo cyashyikirijwe ikigo cy’ubuvuzi cy’Uburayi (EMA).

Ugereranije na liraglutide, semaglutide ifite urunigi rurerure rwa alifatique kandi ikongera hydrophobicity, ariko semaglutide ihindurwa numurongo mugufi wa PEG, kandi hydrophilique yayo irazamuka cyane. Nyuma yo guhindura PEG, ntishobora guhuza gusa na albumine, gutwikira urubuga rwa hydrolysis ya enzymatique ya DPP-4, ariko kandi igabanya gusohora impyiko, ikongerera ubuzima igice cya kabiri cyibinyabuzima, kandi ikagera ku ngaruka zo kuzenguruka igihe kirekire.